Others 8

Others 8

Others 8 related products

Structure Cat No. Product Name CAS No. Product Description
V3471 BMS-066 914946-88-6 BMS-066 is a novel and potent tricyclic pseudokinase inhibitors of IKKβ/Tyk2withIC50sof 9 nM and 72 nM, respectively.
V3516 BMS-346567 953807-31-3 BMS-346567, an analog of Sparsentan, is a novel, potent and selective dual angiotensin II and endothelin A receptor antagonist.
V2070 BMS-37 1675202-20-6 BMS-37 is a novel and potent small molecule inhibitor of the PD-1/PD-L1 protein protein interaction with IC50 value in the range of 6-100 nM in cell free assays.
V2110 BMS-751324 948842-66-8 BMS-751324 is a novel prodrug of BMS-582949 (also known as PS540446) which is a potent and highly selective p38 mitogen-activated protein kinase (p38 MAPK) inhibitor with IC50 of 13nM and is currently in phase II clinical trials for the treatment of rheumatoid arthritis.
V3468 BMS-819881 1197420-05-5 BMS-819881 is a novel and potent antagonist of MCHR1 (Melanin concentrating hormone receptor 1) with minimal hERG activity.
V3469 BMS-830216 1197420-06-6 BMS-830216 isa prodrug of BMS-819881 which is a novel and potent antagonist of MCHR1 (Melanin concentrating hormone receptor 1) with minimal hERG activity.
V3464 BMS-986163 1801151-09-6 BMS-986163, a novel water-soluble phosphate prodrug ofBMS-986169designed for IV administration, is a negative allosteric modulator ofGluN2B which is aN-methyl-d-aspartate receptor subtype.
V3465 BMS-986169 1801151-08-5 BMS-986169 is a novel and potent negative allosteric modulator ofGluN2B which is aN-methyl-d-aspartate receptor subtype.
V3498 BPN14770 1606975-12-5 BPN14770 is a novel and potent allosteric modulator of phosphodiesterase-4 (PDE4) with IC50 values of 8 and 130 nM for human and mouse PDE4D, respectively.
V3946 CA-327 CA-327 is a novel potent, orally available, small molecule and dual inhibitor of TIM3 and PD-L1 with potential anticancer activities.
V3631 Calyculin A 101932-71-2 Calyculin A is a novel, potent, selective and cell-permeable inhibitor of protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A) withIC50s of 0.5 to 1 nM.
V3889 Cannabidiol 13956-29-1 NOT AVAILABLE (CONTROLLED SUBSTANCE; Schedule I drugs under the Controlled Substances Act.
V3473 Cariprazine sulfate Cariprazine (formerly known as MP-214 and RGH-188) is a novel and potent antipsychotic drug candidate that is in late-stage clinical development for the treatment of schizophrenia, as well as for bipolar disorder (manic/mixed and depressive episodes), and as an adjunctive agent for the treatment of major depressive disorder.
V4372 CETUXIMAB 205923-56-4 Cetuximab (C225; C 225; C-225; Erbitux) is a potent and specific chimeric monoclonal antibody approved for cancer treatment.
V3571 dBRD9 2170679-45-3 dBRD9 (dBRD-9) is a novel and potent PROTAC degrader of the BRD9 bromodomain and the cereblon E3 ubiquitin ligase complex with anticancer activity.
V2161 Desciclovir 84408-37-7 Desciclovir is a precursor of acyclovir (ACV), a potent and orally bioactive antiherpetic molecule.
V4390 DFMTI 864864-86-8 DFMTI is a novel compound that can completely block the rmGlu1 L757V glutamate response by acting as anovel mGlu₁ negative allosteric modulator.
V3960 DIETHYL PYIMDC 1821370-64-2 Diethyl pyimDC is a novel inhibitor of human CP4H1 (collagen prolyl 4-hydroxylase 1).
V2612 Diethylmaleate 141-05-9 Diethylmaleate is the diethyl ester of maleic acid and a glutathione-depleting compound that inhibits NFkB.
V3228 DORA-22 1088991-95-0 DORA-22 is a novel, potent and selective dual orexin receptor antagonist that may be useful for insomnia andAD-relevant symptoms.
Contact Us Back to top